神経内科外来シリーズ　2　パーキンソン病外来

出版社： メジカルビュー社
著者：
発行日： 2016-03-01
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784758303835
シリーズ： 神経内科外来シリーズ
電子書籍版： 2016-03-01 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,700 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

7,700 円(税込)

購入する

商品紹介

神経内科医が接する機会の多い神経疾患（頭痛、認知症、パーキンソン病、てんかん、脳卒中）の外来診察に必要なノウハウを、シェーマ、フローチャートなどを多用しコンパクトにまとめて解説しているシリーズ。今回は、「パーキンソン病」を取り上げる。超高齢社会をむかえ、パーキンソン病患者は増えつつあり、今後外来でも診療の機会が増えていくと考えられる。外来で必要な基本的知識、外来の基本的な流れを解説した後、パーキンソン病のさまざまな症状に対する治療をCase Studyをとおして学べるようになっている。また合わせてガイドラインに基づく治療が身につけられるようにした。パーキンソン病外来の基本が身につく1冊である。

目次

  • 神経内科外来シリーズ　2　パーキンソン病外来

    ―目次―

    I. パーキンソン病についての基礎知識
    　パーキンソン病とは
    　パーキンソン病の疫学
    　パーキンソン病の病理
    　遺伝性パーキンソン病

    II. 外来診療の進め方
    　問診のポイント
    　診察
    　運動症状と診断基準・評価スケール
    　非運動症状と評価スケール
    　検査
    　鑑別診断：多系統萎縮症
    　鑑別診断：進行性核上性麻痺
    　鑑別診断：大脳皮質基底核変性症
    　鑑別診断：Lewy小体型認知症
    　鑑別診断：脳血管性パーキンソニズム
    　鑑別診断：正常圧水頭症
    　鑑別診断：薬剤性パーキンソニズム
    　外来診療のポイント

    III. 外来治療の進め方
    　薬物療法：運動症状に対する薬物療法
    　薬物療法：精神症状に対する薬物療法
    　薬物療法：自律神経症状に対する薬物療法
    　リハビリテーション
    　脳深部刺激療法の適応・合併症

    IV. Case Study：症例を通してガイドラインを学ぶ

    V. 外来診療のpitfall

    VI. 社会資源の活用法
    　特定疾患制度、身体障害者制度、介護保険による認定
    　患者支援組織

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I パーキンソン病についての基礎知識

P.8 掲載の参考文献
1) Langston JW. The Parkinson's complex : parkinsonism is just the tip of the iceberg. Ann Neurol 2006 ; 59 : 591-96.
PubMed
2) Rowntree LG. James Parkinosn. Bull Johns Hopk Hosp 1912 ; 23 : 33-45.
 
3) Lewis PA. James Parkinson : the man behind the shaking palsy. J Parkinsons Dis 2012 ; 2 : 181-7.
 
4) Parkinson J. An Essay on the Shaking Palsy. Sherwood, Neely and Jones, London, 1817.
 
5) Charcot JM : Lecon sur les desordres du system nervoeux 1892, p155-7.
 
6) Lewy FH : Paralysis agitans. I. Pathologische Anatomie. In : Lewandowsky M, editor. Handbuck der Neurologie. Vol III/2. Berlin, Springer, 1912.
 
7) Tretikakoff C. Contribution a l'etude Ianatomie pathologique du locus niger de Soemmerring avec quelques deductions relatives a la pathogenie des troubles du tonus musculaire et la maladie de Parkinson (These). Paris : Jouve, 1919.
 
8) Haβler R. Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol (Leipzig) 1938 ; 48 : 387-476.
 
9) Greenfield JG, Bosanquet FD. The brain-stem lesions in Parkinsonism. J Neurol Neurosurg Psychiatry 1953 ; 16 : 213-26.
PubMed
10) Ehringer H, Hornykiewicz O. Verteilung von noradrenaline and dopamine (3-hydroxytyramine) in gehirn des menschen und ihr verhalten bei erkinankungen des extrapyramidalen systems. Klin Wochenschr 1960 ; 38 : 1236-9.
 
11) 佐野勇. 錐体外路系の生化学. 神経進歩 1960 ; 5 : 42-8.
 
12) Birkmayer W, Hornykiewicz O. [The L-3,4-dihydroxyphenylalanine (DOPA) -effect in Parkinsonakinesia]. Wien Klin Wochenschr 1961 ; 73 : 787-8.
 
13) Cotzias GC, Papavasiliou PS, et al. Modification of Parkinsonism-chronic treatment with L-dopa. N Engl J Med 1969 ; 280 : 337-45.
 
14) Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988 ; 51 : 745-52.
 
15) Braak H, Muller CM, et al. Pathology associated with sporadic Parkinson's disease-where does it end? J Neural Transm 2006 Suppl ; 70 : 89-97.
 
16) Kordower JH, Chu Y, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008 ; 14 : 504-6.
PubMed
P.15 掲載の参考文献
1) 古和久典. パーキンソン病の疫学と一生. Progress in Medicine 2012 ; 32 : 12-8.
 
2) 中島健二, 他. パーキンソン病への新たなアプローチ 疫学. Medicament News 2011 ; 2069 : 3-4.
 
3) Yamawaki M, et al. Changes in prevalence and incidence of Parkinson's disease in Japan during a quarter of a century. Neuroepidemiology 2009 ; 32 : 263-9.
PubMed
4) Nakashita S, et al. Clinical assessment and prevalence of parkinsonism in Japanese elderly people. Acta Neurol Scand 2015.
PubMed
5) Pringsheim T, et al. The prevalence of Parkinson's disease : A systematic review and meta-analysis. Mov Disord 2014 ; 29 : 1583-90.
PubMed
6) Muangpaisan W, et al. Systematic review of the prevalence and incidence of Parkinson's disease in Asia. J Epidemiol 2009 ; 19 : 281-93.
 
7) Morioka S, et al. Incidence of Parkinson disease in Wakayama, Japan. J Epeidemiol 2002 ; 12 : 403-7.
PubMed
8) Ishihara LS, et al. Estimated life expectancy of Parkinson's patients compared with the UK population. J Neurol Neurosurg Psychiatry 2007 ; 78 : 1304-9.
PubMed
9) Lo RY, et al. Clinical features in early Parkinson's disease and survival. Arch Neurol 2009 ; 66 : 1353-8.
PubMed
P.21 掲載の参考文献
1) Kosaka K, Oyanagi S, Matsushita M, et al. Presenile dementia with Alzheimer-, Pick- and Lewy-body changes. Acta Neuropathol 1976 ; 36 (3) : 221-33.
PubMed
2) Fujiwara H, Hasegawa M, Dohmae N, et al.alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002 ; 4 (2) : 160-4.
PubMed
3) Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003 ; 24 (2) : 197-211.
PubMed
4) Sumikura H, Takao M, Hatsuta H, et al. Distribution of α-synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons. Acta Neuropathologica Communication, in press.
 
5) Sengoku R, Saito Y, Ikemura M, et al. Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. Journal of neuropathology and experimental neurology 2008 ; 67 : 1072-83.
PubMed
6) Fumimura Y, Ikemura M, Saito Y, et al. Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease. J Neuropathol Exp Neurol 2007 ; 66 : 354-62.
PubMed
7) Ikemura M, Saito Y, Sengoku R, et al. Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 2008 ; 67 : 945-53.
PubMed
8) Saito Y, Shioya A, Sano T, Sumikura H, et al. Lewy body pathology involves the olfactory cells in Parkinson's disease and related disorders. Movement Disorders, in press.
 
P.28 掲載の参考文献
1) 波田野 琢. 家族性パーキンソン病の種類と臨床症状 : これをみたら遺伝子異常を考える. Modern Physician.
 
2) 森聡生, 波田野琢, 他. パーキンソン病の病因遺伝子. Pharma Medica 2015 ; 33 (7) : 15-23.
Medical*Online
3) Polymeropoulos MH, Lavedan C, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997 ; 276 : 2045-7.
PubMed
4) Tokutake T, Ishikawa A, et al. Clinical and neuroimaging features of patient with early-onset Parkinson's disease with dementia carrying SNCA p.G51D mutation. Parkinsonism Relat Disord 2014 ; 20 : 262-4.
PubMed
5) Funayama M, Hasegawa K, et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 2005 ; 57 : 918-21.
PubMed
6) Hatano T, Funayama M, et al. Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease. Neurobiol Aging 2014 ; 35 : 2656 e17-23.
 
7) Ando M, Funayama M, Li Y, et al. VPS35 mutation in Japanese patients with typical Parkinson's disease. Mov Disord 2012 ; 27 : 1413-7.
PubMed
8) Funayama M, Ohe K, et al. CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease : a genome-wide linkage and sequencing study. Lancet Neurol 2015 ; 14 : 274-82.
PubMed
9) Hatano T, Kubo S, et al. Pathogenesis of familial Parkinson's disease : new insights based on monogenic forms of Parkinson's disease. J Neurochem 2009 ; 111 : 1075-93.
PubMed
10) Kawajiri S, Saiki S, Sato S, et al. Genetic mutations and functions of PINK1. Trends Pharmacol Sci 2011 ; 32 : 573-80.
PubMed
11) Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004 ; 304 : 1158-60.
PubMed
12) Hatano Y, Sato K, et al. PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations. Neurology 2004 ; 63 : 1482-5.
PubMed
13) Ning YP, Kanai K, et al. PARK9-linked parkinsonism in eastern Asia : mutation detection in ATP13A2 and clinical phenotype. Neurology 2008 ; 70 : 1491-3.
PubMed
14) Yoshino H, Tomiyama H, et al. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 2010 ; 75 : 1356-61.
PubMed
15) Sidransky E, Nalls MA, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009 ; 361 : 1651-61.
PubMed

II 外来診察の進め方

P.33 掲載の参考文献
1) Jankovic J, Schwartz KS, et al. Re-emergent tremor of Parkinson's disease. J Neurol Neurosurg Psychiat 1999 ; 67 : 646-50.
PubMed
2) Aerts MB, Abdo WF, et al. The "bicycle sign" for atypical parkinsonism. Lancet 2011 ; 377 : 125-6.
PubMed
3) Antonini A, Colosimo C, et al. The PRIAMO study : background, methods and recruitment. Neurological Sci 2008 ; 29 : 61-5.
 
4) Siderowf A, Lang AE. Premotor Parkinson's disease : concepts and definitions. Mov Disord 2012 ; 27 : 608-16.
PubMed
5) 野川茂, 高橋裕秀, ほか. パーキンソン病症状の新しい自記式質問票 (MASAC-PD31) の開発・評価. 臨床神経学 2011 ; 51 : 321-9.
 
P.39 掲載の参考文献
1) Gibb WR, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology 1988 ; 38 (9) : 1402-6.
 
2) Ling H, et al. Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease. Brain 2012 ; 135 : 1141-53.
PubMed
3) Aerts MB, et al. The "bicycle sign" for atypical parkinsonism. Lancet 2011 ; 377 (9760) : 125-6.
PubMed
4) Miwa H, Kondo T. Bicycle sign for differential diagnosis of parkinsonism : is it of use in a hilly country like Japan? J Parkinsons Dis 2011 ; 1 (2) : 167-8..
 
5) Barone P, et al. The PRIAMO study : A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009 ; 24 (11) : 1641-9.
PubMed
6) Bugalho P, Vale J. Brief cognitive assessment in the early stages of Parkinson disease. Cogn Behav Neurol 2011 ; 24 (4) : 169-73.
PubMed
7) Dalrymple-Alford JC, et al. The MoCA : well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010 ; 75 (19) : 1717-25.
 
8) Reginold W, et al. The pill questionnaire in a nondemented Parkinson's disease population. Mov Disord 2012 ; 27 (10) : 1308-11.
 
P.47 掲載の参考文献
1) Kashihara K, Kondo T, Mizuno Y, et al. MDS-UPDRS Japanese Validation Study Group. Official Japanese Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale : validation against the original English version. Mov Disord Clin Pract 2014 ; 1 : 200-12.
PubMed
2) Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988 ; 51 : 745-52.
 
3) Berg D, Postuma RB, Bloem B, et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord 2014 ; 29 : 454-62.
PubMed
4) van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988 ; 19 : 604-7.
 
5) 篠原幸人, 峰松一夫, 天野隆弘, 他. mRS信頼性研究グループ. modified Rankin Scaleの信頼性に関する研究-日本語版判定基準書および問診表の紹介. 脳卒中 2007 ; 29 : 6-13.
 
6) Simuni T, Luo ST, Chou KL, et al. Rankin scale as a potential measure of global disability in early Parkinson's disease. J Clin Neurosci 2013 ; 20 : 1200-3.
PubMed
7) Kieburtz K, Tilley BC, Elm JJ, et al. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NETPD) Investigators. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease : a randomized clinical trial. JAMA 2015 ; 313 : 584-93.
 
P.61 掲載の参考文献
1) Goetz CG, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) : scale presentation and clinimetric testing results. Mov Disord 2008 ; 23 (15) : 2129-70.
PubMed
2) Chaudhuri KR, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease : the NMSQuest study. Mov Disord 2006 ; 21 (7) : 916-23.
PubMed
3) Siderowf A, Lang AE. Premotor Parkinson's disease : concepts and definitions. Mov Disord 2014 ; 27 (5) : 608-16.
 
4) Chaudhuri KR, et al. The Parkinson's disease sleep scale : a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002 ; 73 (6) : 629-35.
 
5) Stiasny-Kolster, K, et al. The REM sleep behavior disorder screening questionnaire-a new diagnostic instrument. Mov Disord 2007 ; 22 (16) : 2386-93.
PubMed
6) Postuma RB, et al. A single-question screen for rapid eye movement sleep behavior disorder : a multicenter validation study. Mov Disord 2012 ; 27 (7) : 913-6.
PubMed
7) Bolitho SJ, et al. Investigating rapid eye movement sleep without atonia in Parkinson's disease using the rapid eye movement sleep behavior disorder screening questionnaire. Mov Disord 2014 ; 29 (6) : 736-42.
PubMed
8) Miyamoto T, et al. The REM sleep behavior disorder screening questionnaire : validation study of a Japanese version. Sleep Med 2009 ; 10 (10) : 1151-4.
PubMed
9) Johns MW. A new method for measuring daytime sleepiness : the Epworth sleepiness scale. Sleep 1991 ; 14 (6) : 540-5.
PubMed
10) 福原俊一, 他. 日本語版 the Epworth Sleepiness Scale (JESS) ～これまで使用されていた多くの「日本語版」との主な差異と改訂. 日呼吸会誌 2006 ; 44 (11) : 896-8.
Medical*Online
11) Starkstein SE, et al. Apathy following cerebrovascular lesions. Stroke 1993 ; 24 (11) : 1625-30.
PubMed
12) Snaith RP, et al. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 1995 ; 167 (1) : 99-103.
PubMed
13) 岡田和悟, 他. やる気スコアを用いた脳卒中後の意欲低下の評価. 脳卒中 1998 ; 20 : 318-23.
Medical*Online
14) Nagayama H, et al. Validity and reliability assessment of a Japanese version of the Snaith-Hamilton pleasure scale. Intern Med 2012 ; 51 (8) : 865-9.
PubMed
15) Emre M, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007 ; 22 (12) : 1689-707 ; quiz 1837.
PubMed
16) Chou KL, et al. A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord 2010 ; 25 (15) : 2501-7.
PubMed
17) Tanaka K, et al. Impulsive compulsive behaviors in Japanese Parkinson's disease patients and utility of the Japanese version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease. J Neurol Sci 331 (1-2) : 76-80.
 
18) Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism : a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988 ; 38 (8) : 1237-44.
PubMed
19) Ford B. Pain in Parkinson's disease. Clin Neurosci 1998 ; 5 (2)) 63-72.
PubMed
20) Brown RG, et al. The Parkinson fatigue scale. Parkinsonism Relat Disord 2005 ; 11 (1) : 49-55.
PubMed
21) Okuma Y, et al. Fatigue in Japanese patients with Parkinson's disease : a study using Parkinson fatigue scale. Mov Disord 2009 ; 24 (13) : 1977-83.
PubMed
22) Witjas T, et al. Nonmotor fluctuations in Parkinson's disease : frequent and disabling. Neurology 2002 ; 59 (3) : 408-13.
PubMed
23) Stacy M, Hauser R. Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease. J Neural Transm 2007 ; 114 (2) : 211-7.
PubMed
24) Kondo T, Takahashi K. Translation and linguistic validation of the Japanese version of the wearing-off questionnaires (WOQ-19 and WOQ-9). Brain Nerve 2011 ; 63 (11) : 1285-92.
 
P.67 掲載の参考文献
1) Orimo S, et al. (123) I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 1999 ; 67 (2) : 189-94.
PubMed
2) Orimo S, et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005 ; 109 (6) : 583-8.
PubMed
3) Orimo S, et al. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism : a systematic review and meta-analysis. Parkinsonism Relat Disord 2012 ; 18 (5) : 494-500.
PubMed
4) Nakajima K. Normal values for nuclear cardiology : Japanese databases for myocardial perfusion, fatty acid and sympathetic imaging and left ventricular function. Ann Nucl Med, 2010 ; 24 (3) : 125-35.
PubMed
5) Djang DS, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med 2012 ; 53 (1) : 154-63.
 
6) Vlaar AM, et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 2008 ; 59 (5) : 258-66.
PubMed
7) Benamer TS, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I] -FPCIT SPECT imaging : the [123I] -FP-CIT study group. Mov Disord 2000 ; 15 (3) : 503-10.
 
8) Walker Z, et al. Dementia with Lewy bodies : a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007 ; 78 (11) : 1176-81.
PubMed
9) Tinazzi M, et al. [123I] FP-CIT SPET imaging in drug-induced Parkinsonism. Mov Disord 2008 ; 23 (13) : 1825-9.
PubMed
10) Schwingenschuh P, et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease : a clinical and electrophysiological study. Mov Disord 2010 ; 25 (5) : 560-9.
PubMed
P.71 掲載の参考文献
1) Papp MI, et al. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989 ; 94 : 79-100.
PubMed
2) Watanabe H, et al. Progression and prognosis in multiple system atrophy : an analysis of 230 Japanese patients. Brain 2002 ; 125 : 1070-83.
PubMed
3) Gilman S, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008 ; 71 : 670-6.
PubMed
4) Kollensperger M, et al. Red flags for multiple system atrophy. Mov Disord 2008 ; 23 : 1093-9.
PubMed
5) Brooks DJ, Seppi K. Neuroimaging Working Group on MSA. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009 ; 24 : 949-64.
 
P.75 掲載の参考文献
1) Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) : report of the NINDSSPSP international workshop. Neurology 1996 ; 47 : 1-9.
PubMed
2) Williams DR, Lees AJ. Progressive supranuclear palsy : clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009 ; 8 : 270-9.
PubMed
P.79 掲載の参考文献
1) Mathew R, Bak TH, Hodges JR. Diagnostic criteria for corticobasal syndrome : a comparative study. J Neurol Neurosurg Psychiatry 2012 ; 83 : 405-10.
PubMed
2) Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013 ; 80 : 496-503.
PubMed
P.83 掲載の参考文献
1) Kosaka K, Oyanagi S, et al. Presenile dementia with Alzheimer-, Pick- and Lewy-body changes. Acta Neuropathol 1976 ; 36 : 221-33.
PubMed
2) McKeith IG, Galasko D, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) : report of the consortium on DLB international workshop. Neurology 1996 ; 47 : 1113-24.
 
3) McKeith IG, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies : third report of the DLB Consortium. Neurology 2005 ; 65 : 1863-72.
PubMed
4) 「認知症疾患治療ガイドライン」作成合同委員会編. 第7章 Lewy小体型認知症 (Parkinson病も含む) In ; 認知症疾患治療ガイドライン 2010. 医学書院, 東京.
 
5) Uchiyama M, Nishio Y, et al. Pareidolias : complex visual illusions in dementia with Lewy bodies. Brain 2012 ; 135 : 2458-69.
PubMed
6) Postuma RB, Arnulf I, et al. A single-question screen for rapid eye movement sleep behavior disorder : a multicenter validation study. Mov Disord 2012 ; 27 : 913-6.
PubMed
7) Stinton C, McKeith I, et al. Pharmacological Management of Lewy Body Dementia : A Systematic Review and Meta-Analysis. Am J Psychiatry 2015 ; 172 : 731-42.
PubMed
P.87 掲載の参考文献
1) Korczyn AD. Vascular parkinsonism-characteristics, pathogenesis and treatment. Nat Rev Neurol 2015 ; 11 : 319-26.
PubMed
2) Vale TC, Caramelli P, et al. Clinicoradiological comparison between vascular parkinsonism and Parkinson's disease. J Neurol Neurosurg Psychiatry 2015 ; 86 : 547-53.
PubMed
3) Yamanouchi H, Nagura H. Neurological signs and frontal white matter lesions in vascular parkinsonism ; a clinicopathologic study. Stroke 1997 ; 28 : 965-9.
PubMed
4) Vizcarra JA, Lang AE, et al. Vascular Parkinsonism : deconstructing a syndrome. Mov Disord 2015 ; 30 : 886-94.
PubMed
5) Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson's diseas : a postmortem study. Acta Neuropathol 2003 ; 105 : 415-9.
 
6) FitzGerald PM, Jankovic J. Lower body parkinsonism : evidence for vascular etiology. Mov Disord 1989 ; 4 : 249-60.
PubMed
P.91 掲載の参考文献
1) Shprecher D, Schwalb J, et al. Normal pressure hydrocephalus : diagnosis and treatment. Curr Neurol Neurosci Rep 2008 ; 8 : 371-6.
PubMed
2) Morishita T, Foote KD, et al. INPH and Parkinson disease : differentiating by levodopa response. Nat Rev Neurol 2010 ; 6 : 52-6.
PubMed
3) Hashimoto M, Ishikawa M, et al. Diagnosis of idiopathic normal pressure hydrocephalus is supported by MRI-based scheme : a prospective cohort study. Cerebrospinal Fluid Res 2010 ; 7 : 18.
PubMed
4) Mori E, Ishikawa M, et al. Guidelines for management of idiopathic normal pressure hydrocephalus : second edition. Neurol Med Chir (Tokyo) 2012 ; 52 : 775-809.
PubMed
5) Toma AK, Papadopoulos MC, et al. Systematic review of the outcome of shunt surgery in idiopathic normal-pressure hydrocephalus. Acta Neurochir 2013 ; 155 : 1977-80.
PubMed
P.95 掲載の参考文献
1) 重篤副作用疾患別対応マニュアル 薬剤性パーキンソニズム (錐体路障害, 錐体外路症状). 厚生労働省.
 
2) Fridman A, Sanotsky Y, et al. Drug-induced Parkinsonism. Erik Walters, Christian Baumann, eds. Parkinson Disease and Other Movement Disorders. VU University Press 2014 ; 372-84. ISBN-978-90-8659-666-9.
 
3) Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol 2012 ; 8 : 15-21.
PubMed
4) Kagi G, Bhatia KP, et al. The Role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry 2010 ; 81 : 5-12.
PubMed
5) Kim JS, Oh YS, et al. Combined use of 123I-metaiodobenzylgua nidine (MIBG) scintigraphy and dopamine transporter (DAT) positron emission tomography (PET) predicts prognosis in drug-induced Parkinsonism (DIP) : a 2-year follow-up study. Arch Gerontol Geriatr 2013 ; 56 : 124-8.
 
P.98 掲載の参考文献
1) 「パーキンソン病治療ガイドライン」作成委員会. 日本神経会監修, パーキンソン病治療ガイドライン 2011, 2011.
 

III 外来治療の進め方

P.113 掲載の参考文献
1) Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004 ; 351 : 2498-508.
PubMed
2) 藤本健一. Parkinson病治療におけるCOMT阻害薬の位置付け. 神経治療学 2007 ; 24 : 533-9.
Medical*Online
3) Gordin A, Kaakkola S, Teravainen H. Clinical advantages of COMT inhibition with entacapone- a review. J Neural Transm (Vienna) 2004 ; 111 : 1343-63.
PubMed
4) Levodopa : management of Parkinson's disease. Mov Disord 2002 ; 17 (Suppl 4) : S23-37.
 
5) パーキンソン病治療ガイドライン 2011, 日本神経学会監修, 医学書院, 2011.
 
6) Tompson DJ, Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole : results of two randomized studies in patients with Parkinson's disease. Clin Ther 2007 ; 29 : 2654-66.
PubMed
7) Kuoppameaki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 2009 ; 65 : 443-55.
PubMed
8) Boroojerdi B, Wolff HM, Braun M, et al. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome. Drugs Today (Barc) 2010 ; 46 : 483-505.
PubMed
P.123 掲載の参考文献
1) Barone P, Antonini A, Colosimo C, et al. The PRIAMO study : A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009 ; 24 : 1641-9.
PubMed
2) Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease : results from an international survey. Mov Disord 2002 ; 17 : 60-7.
 
3) Fenelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci 2010 ; 289 (1-2) : 12-7.
 
4) Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease : a retrospective autopsy study. Lancet Neurol 2005 ; 4 : 605-10.
PubMed
5) Kempster, et al. Relationships between age and late progression of Parkinson's disease : a clinico-pathological study. Brain 2010 ; 133 : 1755-62.
PubMed
6) Goetz CG, et al. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol 2006 ; 63 : 713-6.
PubMed
7) 日本神経学会治療ガイドラインAd Hoc委員会. パーキンソン病治療ガイドライン 2011. 医学書院, 2011.
 
8) 日本精神神経学会監修. DSM-5 精神疾患の診断・統計マニュアル. 医学書院, 2014.
 
9) Miyoshi K, Ueki A, Nagano O. Management of psychiatric symptoms of Parkinson's disease. Eur Neurol 1996 ; 36 Suppl 1 : 49-58.
 
10) Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease : critique and recommendations. Mov Disord 2007 ; 22 : 1077-92.
PubMed
11) Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008 ; 23 : 183-9.
PubMed
12) Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease : a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010 ; 9 : 573-80.
PubMed
13) Rocha FL, Murad MG, Stumpf BP, et al. Antidepressants for depression in Parkinson's disease : systematic review and meta-analysis. J Psychopharmacol 2013 ; 27 : 417-23.
PubMed
14) Paus S, Brecht HM, Koster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003 ; 18 : 659-67.
PubMed
15) Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel : Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999 ; 52 : 1908-10.
PubMed
16) Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008 ; 16 : CD006564.
 
P.131 掲載の参考文献
1) Schrag A, Horsfall L, Walters K, et al. Prediagnostic presentations of Parkinson's disease in primary care : a case-control study. Lancet Neurol 2015 ; 14 : 57-64.
PubMed
2) Postuma RB, Gagnon JF, Pelletier A, et al. Prodromal autonomic symptoms and signs in Boeve BF. Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol 2013 ; 12 : 469-82.
 
3) Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013 ; 80 : 276-81.
PubMed
4) Visser M, van Rooden SM, Verbaan D, et al. A comprehensive model of health-related quality of life in Parkinson's disease. J Neurol 2008 ; 255 : 1580-7.
PubMed
5) Verbaan D, Marinus J, Visser M, et al. Patient-reported autonomic symptoms in Parkinson disease. Neurology 2007 ; 69 : 333-41.
PubMed
6) Tateno F, Sakakibara R, Yokoi Y, et al. Levodopa ameliorated anorectal constipation in de novo Parkinson's disease : The QL-GAT study. Parkinsonism Relat Disord 2011 ; 17 (9) : 662-6.
PubMed
7) Maeda T, Nagata K, Satoh Y, et al. High prevalence of gastroesophageal reflux disease in Parkinson's disease : a questionnaire-based study. Parkinsons Dis 2013 ; 2013 : 742128.
PubMed
8) Heetun ZS, Quigley EM. Gastroparesis and Parkinson's disease : a systematic review. Parkinsonism Relat Disord 2012 ; 18 (5) : 433-40.
PubMed
9) Nakamura T, Hirayama M, Hara T, et al. Role of cardiac sympathetic nerves in preventing orthostatic hypotension in Parkinson's disease. Parkinsonism Relat Disord 2014 ; 4 : 409-14.
PubMed
10) Plaschke M, Trenkwalder P, Dahlheim H,et al. Twenty-four-hour blood pressure profile and blood pressure responses to head-up tilt tests in Parkinson's disease and multiple system atrophy. J Hypertens 1998 ; 16 : 1433-41.
PubMed
11) Ejaz AA, Sekhon IS, Munjal S. Characteristic findings on 24-h ambulatory blood pressure monitoring in a series of patients with Parkinson's disease. Eur J Intern Med 2006 ; 17 : 417-20.
 
12) Devos D, Kroumova M, Bordet R, et al. Heart rate variability and Parkinson's disease severity. J Neural Transm 2003 ; 110 : 997-1011.
PubMed
13) Sakakibara R, Uchiyama T, Yamanishi T, et al. Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm 2008 ; 115 : 443-60.
PubMed
14) 日本神経学会監修. パーキンソン病治療ガイドライン 2011. 医学書院, 2011.
 
P.139 掲載の参考文献
1) 日本神経学会監修「. パーキンソン病治療ガイドライン」作成委員会編集, パーキンソン病治療ガイドライン 2011, 東京, 医学書院.
 
2) Jain SS, Kirshblum SC. Parkinson's disease and other movement disorders. In : Delisa JA, et al, editor. Rehabilitation medicine : principles and practice, 3rd ed. Philadelphia, Lippincott, 1998, p1035-56.
 
3) Keus SH, Munneke M, Nijkrake MJ, et al. Physical therapy in Parkinson's disease : evolution and future challenges. Mov Disord 2009 ; 24 : 1-14.
PubMed
4) Russell JA, Ciucci MR, Connor NP, et al. Targeted exercise therapy for voice and swallow in persons with Parkinson's disease. Brain Res 2010 ; 1341 : 3-11.
PubMed
5) Fox C, Ebersbach G, Ramig L, et al. LSVT LOUD and LSVT BIG : Behavioral Treatment Programs for Speech and Body Movement in Parkinson Disease. Parkinsons Dis 2012 ; 2012 : 391946.
PubMed
6) Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med 2012 ; 366 (6) : 511 -9.
PubMed
7) Tomlinson CL, Patel S, Meek C, et al. Physiotherapy intervention in Parkinson's disease : systematic review and meta-analysis. BMJ 2012 ; 345 : e5004.
PubMed
8) Petzinger GM, Fisher BE, McEwen S, et al. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease. Lancet Neurol 2013 ; 12 (7) : 716-26.
PubMed
9) Morris ME, Iansek R, Matyas TA, et al. Ability to modulate walking cadence remains intact in Parkinson's disease. J Neurol Neurosurg Psychiatry 1994 ; 57 : 1532-4.
PubMed
10) Dam M, Tonin P, Casson S, et al. Effects of conventional and sensory-enhanced physiotherapy on disability of Parkinson's disease patients. Adv Neurol 1996 ; 69 : 551-5.
PubMed
11) McIntosh GC, Brown SH, Rice RR, et al. Rhythmic auditory-motor facilitation of gait patterns in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1997 ; 62 : 22-6.
PubMed
12) Pacchetti C, Aglieri R, Mancini F, et al. Active music therapy and Parkinson's disease : methods. Funct Neurol 1998 ; 13 : 57-67.
PubMed
13) Lim I, van Wegen E, de Goede C, et al. Effects of external rhythmical cueing on gait in patients with Parkinson's disease : a systematic review. Clin Rehabil 2005 ; 19 : 695-713.
 
14) Nieuwboer A, Kwakkel G, Rochester L, et al. Cueing training in the home improves gait-related mobility in Parkinson's disease : the RESCUE trial. J Neurol Neurosurg Psychiatry 2007 ; 78 : 134-40.
 
15) Ito N, Hayashi A, Lin W, et al. Music therapy in Parkinson's disease : improvement of Parkinsonian gait and depression with rhythmic auditory stimulation. In : Nakada T, editor. Integrated human brain science : theory, method application (music). New York, Elsevier Science, 2000, p435-43.
 
16) 林明人. Parkinson病と音楽療法. 神経内科 2007 ; 67 : 236-42.
 
17) 林明人. パーキンソン病に効く音楽療法CDブック. マキノ出版, 2012.
 
P.147 掲載の参考文献
1) 服部信孝 (監), 大山彦光 (訳), 下泰司 (訳), 梅村淳 (訳). 運動障害診療マニュアル. 医学書院, 2013.
 
2) Okun MS. Deep-brain stimulation for Parkinson's disease. The New England journal of medicine 2012 ; 367 : 1529-38.
PubMed
3) Wichmann T, DeLong MR. Oscillations in the basal ganglia. Nature 1999 ; 400 : 621-2.
PubMed
4) 梅村淳, 大山彦光, 下泰司, 服部信孝. 神経内科医に必要な脳深部刺激療法に関する知識. 臨床神経学 2013 ; 53 : 911-4.
 
5) Oyama G, Shimo Y, Natori S, et al. Acute effects of bilateral subthalamic stimulation on decision-making in Parkinson's disease. Parkinsonism & related disorders 2011 ; 17 : 189-93.
PubMed
6) Kim YE, Kim HJ, Kim HJ, et al. Impulse control and related behaviors after bilateral subthalamic stimulation in patients with Parkinson's disease. Journal of Clinical Neuroscience 2013 ; 20 : 964-69.
PubMed
7) Charles PD, Van Blercom N, Krack P, et al : Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 2002 ; 59 : 932-4.
PubMed
8) Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. The New England journal of medicine 2013 ; 368 : 610-22.
PubMed
9) Charles D, Konrad PE, Neimat JS, et al : Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease. Parkinsonism & related disorders 2014 ; 20 ; 731-7.
PubMed
10) Limotai N, Oyama G, Go C, et al. Addiction-like manifestations and Parkinson's disease : a large single center 9-year experience. Int J Neurosci 2012 ; 122 ; 145-53.
PubMed
11) Mann JM, Foote KD, Garvan CW, et al. Brain penetration effects of microelectrodes and DBS leads in STN or GPi. J Neurol Neurosurg Psychiatry 2009 ; 80 ; 794-7.
PubMed
12) Oyama G, Shimo Y, Umemura A, et al. Troubleshooting in hospitalized Parkinson's disease patients with a history of deep brain stimulation of the subthalamic nucleus. Neurol Clin Neurosci 2014 ; 2 : 88-192.
 

IV Case Study : 症例を通してガイドラインを学ぶ

P.152 掲載の参考文献
1) 藤本健一, 中野今治. 臨床神経学 2009 ; 49 : 1133.
 
2) Yamashiro K, Komine-Kobayashi M, Hatano T, et al. The frequency of cardiac valvular regurgitation in Parkinson's disease. Mov Disord 2008 ; 23 : 935-41.
PubMed
3) Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002 ; 303 : 791-804.
 
P.156 掲載の参考文献
1) パーキンソン病治療ガイドライン 2011, 日本神経学会監修, 医学書院, 2011年.
 
2) Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008 ; (2) : CD006564.
PubMed
P.160 掲載の参考文献
1) Aarsland D, Kvaloy JT, Andersen K, et al. The effect of age of onset of PD on risk of dementia. J Neurol 2007 ; 254 : 38-45.
PubMed
2) Buter TC, van den Hout A, Matthews FE, et al. Dementia and survival in Parkinson disease, a 12-year population study. Neurology 2008 ; 70 : 1017-22.
PubMed
3) Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008 ; (2) : CD006564.
PubMed
4) 日本神経学会監修. パーキンソン病治療ガイドライン 2011, 医学書院, 2011年.
 
P.165 掲載の参考文献
1) パーキンソン病治療ガイドライン作成委員会編. パーキンソン病治療ガイドライン 2011. 日本神経学会監修, 医学書院, 東京.
 
2) Grosset D, Antonini A, Canesi M, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009 ; 24 : 826-32.
 
P.168 掲載の参考文献
1) Weintraub D. Impulse control disorders in Parkinson's disease : prevalence and possible risk factors. Parkinsonism and related Disorders 2009 ; 15 (Suppl 3) : 110-3.
 
2) パーキンソン病治療ガイドライン 2011. パーキンソン病治療ガイドライン作成委員会編. 日本神経学会監修. 医学書院, 東京.
 
3) Sawada H, Oeda T, Kuno S, et al. Amantadine Study Group. Amantadine for dyskinesias in Parkinson's disease : a randomized controlled trial. PLoS One 2010 ; 5 : e15298.
 
4) Maeda T, Nagata K, Yoshida Y, et al. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res 2005 ; 1046 : 230-3.
PubMed
5) 神成一哉, 倉橋幸造, 冨山誠彦, 他. 選択的5-HT1A受容体アゴニスト, クエン酸タンドスピロンのL-DOPA-induced dyskinesia軽減効果. 脳神経 2002 ; 54 : 133-7.
 
P.171 掲載の参考文献
1) Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology1996 ; 46 : 1470.
PubMed
2) 山元敏正ほか. 起立性低血圧を伴うパーキンソン病では副腎髄質の交感神経と圧受容器反射機能は保たれる. 自律神経 2011 ; 48 : 251-7.
 
3) 山元敏正, ほか. パーキンソン病の自律神経症状. Brain Nerve 2012 ; 64 : 394-402.
 
4) 「パーキンソン病治療ガイドライン」作成委員会編. 日本神経学会監修. CQ4-9 起立性低血圧の治療はどうするのか. パーキンソン病治療ガイドライン 2011, 医学書院, 東京, 2011, p175-7.
 
P.175 掲載の参考文献
1) Sakakibara R, Kishi M, Ogawa E, et al. Bladder, bowel, and sexual dysfunction in Parkinson's disease. Parkinsons Dis 2011 ; 2011 : 924605. Epub 2011. PMID : 21918729.
 
2) Recasens A, Dehay B. Alpha-synuclein spreading in Parkinson's disease. Front Neuroanat 2014 ; 8 : 159. doi : 10.3389/fnana. 2014. 00159. eCollection 2014.
 
3) Tateno H, Sakakibara R, Tateno F, et al. MIBG myocardial scintigraphy identifies premotor PD during a negative DAT scan period. J Am Geri Soc 2015, in press.
 
4) Tateno H, Sakakibara R, Shiina S, et al. Transdermal dopamine agonist ameliorates gastric emptying in Parkinson's disease. J Am Geri Soc 2015, in press.
 
5) Sakakibara R, Doi H, Sato M, et al. Nizatidine ameliorates slow transit constipation in Parkinson's disease. J Am Geriatr Soc 2015 ; 63 : 399-401.
PubMed
P.180 掲載の参考文献
1) Chaudhuri KR, Healy DG, Schapira AHV. National Institute for Clinical ; Exellence. Non-motor symptoms of Parkinson's disease : diagnosis and management. Lancet Neurol 2006 ; 5 : 235-45.
 
2) Sakakibara R, Fowler CJ. Bladder dysfunction in Parkinson's Disease. In : Non-Motor Symptoms of Parkinson's Disease. Second edition. Eidtors : Chaudhuri KR, Tolosa E, Schapira A, Poewe W, Oxford University Press, UK, 2014.
 
3) Herzog J, Weiss PH, Assmus A, et al. Improved sensory gating of urinary bladder afferents in Parkinson's disease following subthalamic stimulation. Brain 2008 ; 131 (Pt 1) : 132-45.
 
4) 榊原隆次, 編著. 神経因性膀胱ベッドサイドマニュアル. 中外医学社, 東京, 2014.
 
5) Sakakibara R, Panicker J, Finazzi-Agro E, et al. Parkinson's Disease Subcomittee, The Neurourology Promotion Committee in The International Continence Society. A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourol Urodyn 2015 Mar 25. doi : 10.1002/nau.22764. [Epub ahead of print] PMID : 2581003
 
P.184 掲載の参考文献
1) American Academy of Sleep Medicine. International Classification of Sleep Disorders, 2nd ed. Diagnostic and Coding Manual. Westchester, Illinois, American Academy of Sleep Medicine, 2005.
 
2) Boeve BF, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007 ; 130 : 2770-88.
PubMed
3) パーキンソン病治療ガイドライン作成委員会編. パーキンソン病治療ガイドライン 2011. 東京, 医学書院, 146-66, 2011.
 
4) Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-based Medicine Review Update : Treatment for the Non-motor symptoms of Parkinson's disease. Mov Disord 2011 ; 26 ; S43-80.
 
5) Aurora RN, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 2010 ; 6 : 85-95.
PubMed
P.188 掲載の参考文献
1) 日本神経学会治療ガイドラインAd Hoc委員会. パーキンソン病治療ガイドライン 2011. 医学書院, 2011.
 
P.192 掲載の参考文献
1) 日本神経学会治療ガイドラインAd Hoc委員会. パーキンソン病治療ガイドライン 2011. 医学書院, 2011.
 
2) Weintraub D, et al. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 2011 ; 68 : 899-904.
PubMed
P.197 掲載の参考文献
1) Santangelo G, et al. Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia. J Neurol 2009 ; 256 : 632-8.
PubMed
2) 岡田和悟, 他. やる気スコアを用いた脳卒中後の意欲低下の評価. 脳卒中 1998 ; 20 : 318-23.
Medical*Online
3) Nagayama H, et al. Validity and reliability assessment of a Japanese version of the Snaith-Hamilton pleasure scale. Intern Med 2012 ; 51 : 865-9.
PubMed
4) 高橋良輔, 他. うつの治療はどうするか. 「パーキンソン病治療ガイドライン」作成委員会編, パーキンソン病治療ガイドライン 2011. 東京, 医学書院, 152-5, 2011.
 
5) Miura S, et al. Anhedonia in Japanese patients with Parkinson's disease : Analysis using the Snaith-Hamilton Pleasure Scale. Clin Neurol Neurosurg 2012 ; 114 : 352-5.
PubMed
P.201 掲載の参考文献
1) Inoue T, et al. Depression and major depressive disorder in patients with Parkinson's disease. Mov Disord 2010 ; 25 : 44-9.
PubMed
2) Schrag A, et al. Depression rating scales in Parkinson's disease : critique and recommendations. Mov Disord 2007 ; 22 : 1077-92.
PubMed
3) Aarsland D et al. Depression in Parkinson diseas-epidemiology, mechanisms and management. Nat Rev Neurol 2012 ; 8 : 35-47.
 
4) 高橋良輔, 他. うつの治療はどうするか. 「パーキンソン病治療ガイドライン」作成委員会編, パーキンソン病治療ガイドライン 2011. 東京, 医学書院, 152-5, 2011.
 
P.205 掲載の参考文献
1) Frucht S, Rogers JD, et al. Falling asleep at the wheel : motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999 ; 52 : 1908-10.
PubMed
2) Hobson DE, Lang AE, et al. Excessive daytime sleepiness and sudden- onset sleep in Parkinson disease : a survey by the Canadian Movement Disorders Group. JAMA 2002 ; 287 : 455-63.
PubMed
3) Paus S, Brecht HM, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003 ; 18 : 659-67.
PubMed
4) Tholfsen LK, Larsen JP, et al. Development of excessive daytime sleepiness in early Parkinson disease. Neurology 2015 ; 85 : 162-8.
PubMed
5) パーキンソン病治療ガイドライン作成委員会編. 日本神経学会監修, パーキンソン病治療ガイドライン 2011. 医学書院, 東京, 2011.
 
P.209 掲載の参考文献
1) Paus S, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003 ; 18 : 659-67.
PubMed
2) 福原俊一, 他. 日本語版the Epworth Sleepiness Scale (JESS). 日呼吸会誌 2006 ; 44 : 896-8.
Medical*Online
3) Mehta SH, et al. Sleep disorders associated with Parkinson's disease : role of dopamine, epidemiology, and clinical scales and assessment. CNS Spectr 2008 ; 13 : S4.
 
4) パーキンソン病治療ガイドライン作成委員会編. パーキンソン病治療ガイドライン 2011. 東京, 医学書院, 146-66, 2011.
 
5) Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-based Medicine Review Update : Treatment for the Non-motor symptoms of Parkinson's disease. Mov Disord 2011 ; 26 : S43-80.
 
P.213 掲載の参考文献
1) Parkinson J. An essay on the shaking palsy. London : Whittingham and Rowland, 1817.
 
2) 藤本健一. 治療上の問題点と対策「姿勢異常」. 日本臨増刊号 2009 ; 67 : 475-8.
 
3) 藤本健一, 池口邦彦, 他. Parkinson病治療薬による姿勢異常の全国疫学調査. 厚生労働科学研究補助金 難治性疾患克服研究事業 神経変性疾患に関する調査研究 平成22年度総括・分担研究報告書. 2011, pp188-90.
 
4) Furusawa Y, Mukai Y, et al. Long-term effect of repeated lidocaine injections into the external oblique for upper camptocormia in Parkinson's disease. Parkinsonism Relat Disord 2013 ; 19 : 350-4.
 
5) 藤本健一. 姿勢異常を伴う神経疾患. 脊椎脊髄 2013 ; 26 : 633-40.
 
P.216 掲載の参考文献
1) 藤本健一. Parkinson病における病的賭博. 神経内科 2007 ; 66 : 88-93.
 
2) 藤本健一. 病的賭博とパーキンソン病. Brain Nerve 2008 ; 60 : 1039-46.
 
3) 藤本健一. パーキンソン病治療に伴う脱抑制性の行動異常. Brain Nerve 2012 ; 64 : 373-83.
 
4) Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007 ; 64 : 1089-96.
PubMed
5) Diagnostic and Statistical Mannual of Mental Disorders 4th ed. American Psychiatric Association, Washington, 1994.
 
P.221 掲載の参考文献
1) 日本神経学会「パーキンソン病治療ガイドライン」作成委員会. パーキンソン病治療ガイドライン 2011. 医学書院, 2011.
 

V 外来診療のpitfall

P.227 掲載の参考文献
1) Gilman S, et al. Consensus statement Second on the diagnosis of multiple system atrophy. J Neurol Sci 1999 ; 163 : 94-8.
 
2) Gilman S, et al. Second statement on the diagnosis of multiple system atrophy. Neurology 2008 ; 71 : 670-6.
PubMed
3) Fanciulli A, et al. Multiple-system Atrophy. N Engl J Med 2015 ; 372 : 249-63.
PubMed
4) Watanabe H, et al : Progression and prognosis in multiple system atrophy : an analysis of 230 Japanese patients. Brain 2002 ; 125 : 1070-83.
PubMed
P.231 掲載の参考文献
1) Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol 2012 ; 8 : 15-21.
PubMed
2) Tinazzi M, Antonini A, et al. Clinical and [123I] FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol 2009 ; 256 : 910-5.
PubMed
3) Kim JS, Oh YS, et al. Combined use of 123I-metaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter (DAT) positron emission tomography (PET) predicts prognosis in drug-induced Parkinsonism (DIP) : a 2-year follow-up study. Arch Gerontol Geriatr 2013 ; 56 : 124-8.
 
4) Brigo F, Erro R, et al. Differentiating drug-induced parkinsonism from Parkinson's disease : an update on non-motor symptoms and investigations. Parkinsonism Relat Disord 2014 ; 20 : 808-14.
PubMed
P.236 掲載の参考文献
1) McKeith IG, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies : third report of the DLB Consortium. Neurology 2005 ; 65 : 1863-72.
PubMed
2) 中室卓也, 二村直伸, 他. パーキンソン病における睡眠中の叫びの臨床的検討. 臨床神経学 1998 ; 38 : 457-60.
 
3) Siderowf A, Lang AE. Premotor Parkinson's disease : concepts and definitions. Mov disord 2012 ; 27 : 608-x16.
PubMed
4) Postuma RB, Lang AE, et al. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006 ; 66 : 845-51.
PubMed
5) Baba T, Kikuchi A, et al. Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease : a 3 year longitudinal study. Brain 2012 ; 135 : 161-9.
PubMed
P.241 掲載の参考文献
1) 池邊紳一郎, 森 秀生, 角野禎子, 他. 進行性の歩行及び注視障害を認めた77歳男性. 脳と神経 2000 ; 52 : 269-279. 水野美邦, 森秀生編. Neurological CPC. 順天堂大学脳神経内科, 臨床・病理カンファレンス, 医学書院 収載.
 
2) Wadia PM, Lang AE. The many faces of corticobasal degeneration. Parkinsonism Relat Disord 2007 ; 13 Suppl 3 : S336-40.
 
3) Mathew R, Bak TH, Hodges JR. Diagnostic criteria for corticobasal syndrome : a comparative study. J Neurol Neurosurg Psychiatry 2012 ; 83 : 405-10.
PubMed
4) Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013 ; 80 : 496-503.
PubMed
P.243 掲載の参考文献
1) Ells GL. Subdural hematoma in the elderly. Emerg Med Clin North Am 1990 ; 8 : 281-94.
 
2) Gelabert-Gonzalez M, et al. Parkinsonism secondary to subdural haematoma. Neurosurg Rev 2012 ; 35 : 457-60.
PubMed

VI 社会資源の活用法

P.250 掲載の参考文献
1) 厚生労働省健康局疾病対策課. 難病医療費助成制度概要, 平成27年.
 
2) 厚生労働省社会・援護局障害保健福祉部. 身体障害者障害程度等級表の解釈, 平成15年.
 
3) 厚生労働省社会・援護局障害福祉部. 障害者総合支援法対象疾病 (難病) の見直しについて, 平成27年.
 
4) 介護保険法施行令 第2条, 平成10年.
 

書評

最近チェックした商品履歴

Loading...